Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Maribel Acevedo-Quiñones et al.|New England Journal of Medicine|2024Cited by 260
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trialBeatriz Grinsztejn, Jean‐Michel Molina, Nathalie De Castro et al.|The Lancet Infectious Diseases|2014Cited by 98
Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following CoemergenceCarlo Fischer, Jan Felix Drexler, Fernando A. Bozza et al.|mSphere|2020Cited by 35
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling studyCarlo Fischer, Jan Felix Drexler, Anna Frühauf et al.|The Lancet Infectious Diseases|2025Cited by 31
Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populationsCaroline S. Myers, Juan Carlos Ramos, Denis Miyashiro et al.|Haematologica|2024Cited by 7